Franklin Resources Inc. Makes New Investment in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Franklin Resources Inc. acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 36,317 shares of the biopharmaceutical company’s stock, valued at approximately $1,499,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Erste Asset Management GmbH acquired a new stake in Agios Pharmaceuticals in the 3rd quarter valued at $97,199,000. Marshall Wace LLP lifted its holdings in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $33,767,000. Frazier Life Sciences Management L.P. grew its position in shares of Agios Pharmaceuticals by 66.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after purchasing an additional 348,808 shares during the period. Finally, Candriam S.C.A. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth about $13,922,000.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AGIO shares. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Raymond James restated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $33.40 on Friday. The business’s 50 day moving average price is $48.89 and its 200 day moving average price is $46.18. The company has a market cap of $1.90 billion, a price-to-earnings ratio of 2.94 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a one year low of $20.96 and a one year high of $62.58.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.